RT Journal
A1 Agarwal N
T1 HOrmonal therapy for prostate cancer in men with heart disease
JF JAMA
JO JAMA
YR 2010
FD January 6
VO 303
IS 1
SP 32
OP 33
DO 10.1001/jama.2009.1931
UL http://dx.doi.org/10.1001/jama.2009.1931
AB 
To the Editor: In the study by Dr Nanda and colleagues,1 although the adjusted hazard ratio for all-cause mortality with neoadjuvant androgen deprivation therapy (ADT) was less than 1.0 in men without comorbidities, the absolute death rate was higher in men who received neoadjuvant ADT (9.6%) than in men who did not (6.7%). Although the authors state that this can be explained by the more unfavorable prostate cancer prognostic factors for the neoadjuvant ADT group, the possibility that ADT promoted castration-refractory disease and all-cause mortality cannot be ruled out.